Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a Novel 2+1 T-Cell Targeting Bispecific Antibody for Mesothelin-Expressing Cancers
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.